Increased transcript diversity: novel splicing variants of Machado-Joseph disease gene (ATXN3)
- PMID: 19714377
- DOI: 10.1007/s10048-009-0216-y
Increased transcript diversity: novel splicing variants of Machado-Joseph disease gene (ATXN3)
Abstract
Machado-Joseph disease (MJD) is a late-onset neurodegenerative disorder that presents clinical heterogeneity not completely explained by its causative mutation. MJD is caused by an expansion of a CAG tract at exon 10 of the ATXN3 gene (14q32.1), which encodes for ataxin-3. The main goal of this study was to analyze the occurrence of alternative splicing at the ATXN3 gene, by sequencing a total of 415 cDNAs clones (from 20 MJD patients and 14 controls). Two novel exons are described for the ATXN3 gene. Fifty-six alternative splicing variants, generated by four types of splicing events, were observed. From those variants, 50 were not previously described, and 26 were only found in MJD patients samples. Most of the variants (85.7%) present frameshift, which leads to the appearance of premature stop codons. Thirty-seven of the observed variants constitute good targets to nonsense-mediated decay, the remaining are likely to be translated into at least 20 different isoforms. The presence of ataxin-3 domains was assessed, and consequences of domain disruption are discussed. The present study demonstrates high variability in the ATXN3 gene transcripts, providing a basis for further investigation on the contribution of alternative splicing to the MJD pathogenic process, as well as to the larger group of the polyglutamine disorders.
Similar articles
-
Transcript diversity of Machado-Joseph disease gene (ATXN3) is not directly determined by SNPs in exonic or flanking intronic regions.J Mol Neurosci. 2013 Mar;49(3):539-43. doi: 10.1007/s12031-012-9832-3. Epub 2012 Jun 16. J Mol Neurosci. 2013. PMID: 22706685
-
Parkinsonian phenotype in Machado-Joseph disease (MJD/SCA3): a two-case report.BMC Neurol. 2011 Oct 24;11:131. doi: 10.1186/1471-2377-11-131. BMC Neurol. 2011. PMID: 22023810 Free PMC article.
-
The genomic structure and expression of MJD, the Machado-Joseph disease gene.J Hum Genet. 2001;46(7):413-22. doi: 10.1007/s100380170060. J Hum Genet. 2001. PMID: 11450850
-
Toward understanding Machado-Joseph disease.Prog Neurobiol. 2012 May;97(2):239-57. doi: 10.1016/j.pneurobio.2011.11.006. Epub 2011 Nov 23. Prog Neurobiol. 2012. PMID: 22133674 Free PMC article. Review.
-
Machado-Joseph disease/spinocerebellar ataxia type 3.Handb Clin Neurol. 2012;103:437-49. doi: 10.1016/B978-0-444-51892-7.00027-9. Handb Clin Neurol. 2012. PMID: 21827905 Free PMC article. Review.
Cited by
-
Transcript diversity of Machado-Joseph disease gene (ATXN3) is not directly determined by SNPs in exonic or flanking intronic regions.J Mol Neurosci. 2013 Mar;49(3):539-43. doi: 10.1007/s12031-012-9832-3. Epub 2012 Jun 16. J Mol Neurosci. 2013. PMID: 22706685
-
Mouse ataxin-3 functional knock-out model.Neuromolecular Med. 2011 Mar;13(1):54-65. doi: 10.1007/s12017-010-8137-3. Epub 2010 Oct 14. Neuromolecular Med. 2011. PMID: 20945165 Free PMC article.
-
Physiological and pathophysiological characteristics of ataxin-3 isoforms.J Biol Chem. 2019 Jan 11;294(2):644-661. doi: 10.1074/jbc.RA118.005801. Epub 2018 Nov 19. J Biol Chem. 2019. PMID: 30455355 Free PMC article.
-
ATXN3: a multifunctional protein involved in the polyglutamine disease spinocerebellar ataxia type 3.Expert Rev Mol Med. 2024 Sep 25;26:e19. doi: 10.1017/erm.2024.10. Expert Rev Mol Med. 2024. PMID: 39320846 Free PMC article. Review.
-
Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies.Mol Neurobiol. 2014 Jun;49(3):1513-31. doi: 10.1007/s12035-013-8596-2. Epub 2013 Nov 29. Mol Neurobiol. 2014. PMID: 24293103 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases